There’s a new Phase 3 clinical trial for an oral medication, taken one time per day, that will reduce testosterone for advanced prostate cancer.
Myovant Sciences is testing their new drug, called Relugolix in a trial called, HERO. Relugolix lowers testosterone by inhibiting pituitary release of luteinizing hormone and follicle-stimulating hormone.
Todays testosterone reducing therapies require injections and the most commonly used such as Lupron start off by raising testosterone and causing a clinical flare of symptoms. Relugolix decreases testosterone within days of initiation and might enable quick testosterone recovery when treatment ends. That would be super for men thinking abou intermittent therapy.
Seek out clinical trial information for HERO in your host country. If in the USA, go to http://www.centerwatch.com/ctrc/malecare/